Connection
Prasad Padala to Central Nervous System Stimulants
This is a "connection" page, showing publications Prasad Padala has written about Central Nervous System Stimulants.
|
|
Connection Strength |
|
|
|
|
|
2.996 |
|
|
|
-
Padala PR, Padala KP, Samant RS, James GA. Improvement of neuronal integrity with methylphenidate treatment for apathy in Alzheimer's disease. Int Psychogeriatr. 2020 04; 32(4):539-540.
Score: 0.583
-
Padala PR, Padala KP, Lensing SY, Ramirez D, Monga V, Bopp MM, Roberson PK, Dennis RA, Petty F, Sullivan DH, Burke WJ. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2018 02 01; 175(2):159-168.
Score: 0.494
-
Padala PR, Padala KP, Sullivan DH, Reynolds DW, Desouza CV, Potter JF, Burke WJ. Improvement of glycemic control using methylphenidate treatment of apathy: a preliminary report. J Am Geriatr Soc. 2012 Jul; 60(7):1383-4.
Score: 0.345
-
Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, Petty F. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010 Apr; 18(4):371-4.
Score: 0.295
-
Padala PR, Burke WJ, Bhatia SC. Modafinil therapy for apathy in an elderly patient. Ann Pharmacother. 2007 Feb; 41(2):346-9.
Score: 0.237
-
Padala PR, Burke WJ, Bhatia SC, Petty F. Treatment of apathy with methylphenidate. J Neuropsychiatry Clin Neurosci. 2007; 19(1):81-3.
Score: 0.235
-
Zeng L, Perin J, Gross AL, Shade D, Lanct?t KL, Lerner AJ, Mintzer JE, Brawman-Mintzer O, Padala PR, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Herrmann N, Rosenberg PB. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). Int J Geriatr Psychiatry. 2024 Jun; 39(6):e6108.
Score: 0.197
-
Lanct?t KL, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer RW, Vieira D, Coulibaly H, Rosenberg PB, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Burke WJ, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). Int Psychogeriatr. 2023 11; 35(11):664-672.
Score: 0.182
-
Mintzer J, Lanct?t KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, Padala PR, Brawman-Mintzer O, Porsteinsson AP, Lerner AJ, Craft S, Levey AI, Burke W, Perin J, Shade D. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021 11 01; 78(11):1324-1332.
Score: 0.165
-
Scherer RW, Drye L, Mintzer J, Lanct?t K, Rosenberg P, Herrmann N, Padala P, Brawman-Mintzer O, Burke W, Craft S, Lerner AJ, Levey A, Porsteinsson A, van Dyck CH. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018 Jan 18; 19(1):46.
Score: 0.127
-
Desouza CV, Padala PR, Haynatzki G, Anzures P, Demasi C, Shivaswamy V. Role of apathy in the effectiveness of weight management programmes. Diabetes Obes Metab. 2012 May; 14(5):419-23.
Score: 0.083
-
Padala PR, Petty F, Bhatia SC. Methylphenidate may treat apathy independent of depression. Ann Pharmacother. 2005 Nov; 39(11):1947-9.
Score: 0.054
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|